Revvity announced it will release its fourth quarter and full year 2025 financial results before market open on Monday, February 2, 2026, and host a conference call at 8:00 a.m. ET the same day. Prahlad Singh, President and CEO, and Max Krakowiak, CFO, will review preliminary results showing fourth quarter reported revenue growth of approximately 6% and organic growth of 4%, driving Q4 revenue to roughly $772 million. For the full year, reported and organic revenue are expected to increase by about 4% and 3%, respectively, yielding full year revenue near $2,855 million. Management now anticipates adjusted earnings per share for 2025 will exceed the upper end of its prior $4.90–$5.00 guidance. Investors can access a live audio webcast via the Company’s website, and a slide presentation will be posted in the Investors section following the call.

Revvity has entered into a collaboration with Eli Lilly to integrate TuneLab AI drug discovery models into Revvity’s Signals Xynthetica platform, enabling secure, federated learning across geographically dispersed research sites. Under the agreement, Revvity will deploy a containerized version of TuneLab that allows partners to train proprietary algorithms on local data sets without transferring raw data, preserving confidentiality and compliance with data sovereignty regulations. The initial phase targets multi-modal analytics for small-molecule screening and biomarker identification, with joint benchmarks set to accelerate lead optimization timelines by up to 30%. Both companies will co-develop user interfaces and workflows, with pilot deployments scheduled for H1 2026 and broader rollout in late 2026.